Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Ionis Pharmaceuticals stock in Canada | $37.25
Own Ionis Pharmaceuticals shares in just a few minutes.
Ionis Pharmaceuticals is a biotechnology business based in the US. Ionis Pharmaceuticals stocks (IONS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $37.25 – an increase of 5.58% over the previous week. Ionis Pharmaceuticals employs 757 staff and has a trailing 12-month revenue of around $707.5 million.
How to buy Ionis Pharmaceuticals stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: IONS in this case.
- Research Ionis Pharmaceuticals stocks. The platform should provide the latest information available.
- Buy your Ionis Pharmaceuticals stocks. It's that simple.
What's in this guide?
- Can I buy shares in Ionis Pharmaceuticals?
- Has coronavirus impacted Ionis Pharmaceuticals shares?
- Ionis Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Ionis Pharmaceuticals stock a buy or sell?
- Ionis Pharmaceuticals performance over time
- Can I short Ionis Pharmaceuticals shares?
- Is Ionis Pharmaceuticals suitable for ethical investing?
- Are Ionis Pharmaceuticals shares over-valued?
- Ionis Pharmaceuticals's financials
- How volatile are Ionis Pharmaceuticals shares?
- Does Ionis Pharmaceuticals pay a dividend?
- Other common questions
How has Coronavirus impacted Ionis Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, Ionis Pharmaceuticals's stock price has had significant negative movement.
Its last market close was $37.25, which is 38.42% down on its pre-crash value of $60.49 and 5.56% down on the lowest point reached during the March crash when the stocks fell as low as $39.32.
If you had bought $1,000 worth of Ionis Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $711.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $637.35.
Ionis Pharmaceuticals stock priceUse our graph to track the performance of IONS stocks over time.
Ionis Pharmaceuticals stocks at a glance
|Latest market close||$37.25|
|52-week range||$34.43 - $64.37|
|50-day moving average||$37.4789|
|200-day moving average||$46.3451|
|Wall St. target price||$57.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.518|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Ionis Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Ionis Pharmaceuticals price performance over time
|1 month (2021-06-25)||-4.32%|
|3 months (2021-04-26)||-14.62%|
Is Ionis Pharmaceuticals under- or over-valued?
Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ionis Pharmaceuticals's PEG ratio
Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Ionis Pharmaceuticals's EBITDA
Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$128.6 million.
The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Ionis Pharmaceuticals financials
|Revenue TTM||USD$707.5 million|
|Gross profit TTM||USD$182.2 million|
|Return on assets TTM||-3.9%|
|Return on equity TTM||-46.8%|
|Market capitalisation||USD$5.3 billion|
TTM: trailing 12 months
How to short and sell Ionis Pharmaceuticals stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "IONS.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 9.0 million Ionis Pharmaceuticals stocks held short by investors – that's known as Ionis Pharmaceuticals's "short interest". This figure is 0.4% up from 9.0 million last month.
There are a few different ways that this level of interest in shorting Ionis Pharmaceuticals stocks can be evaluated.
Ionis Pharmaceuticals's "short interest ratio" (SIR)
Ionis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ionis Pharmaceuticals stocks currently shorted divided by the average quantity of Ionis Pharmaceuticals stocks traded daily (recently around 1.6 million). Ionis Pharmaceuticals's SIR currently stands at 5.57. In other words for every 100,000 Ionis Pharmaceuticals stocks traded daily on the market, roughly 5570 stocks are currently held short.
However Ionis Pharmaceuticals's short interest can also be evaluated against the total number of Ionis Pharmaceuticals stocks, or, against the total number of tradable Ionis Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ionis Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 Ionis Pharmaceuticals stocks in existence, roughly 60 stocks are currently held short) or 0.0672% of the tradable stocks (for every 100,000 tradable Ionis Pharmaceuticals stocks, roughly 67 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Ionis Pharmaceuticals.
Find out more about how you can short Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Ionis Pharmaceuticals's total ESG risk score
Total ESG risk: 36.64
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 12/31/2018) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Ionis Pharmaceuticals's environmental score
Environmental score: 5.18/100
Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Ionis Pharmaceuticals's social score
Social score: 26.17/100
Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Ionis Pharmaceuticals's governance score
Governance score: 13.29/100
Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Environmental, social, and governance (ESG) summary
|Total ESG score||36.64|
|Total ESG percentile||62.18|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
Ionis Pharmaceuticals stock dividends
We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Ionis Pharmaceuticals stock price volatility
Over the last 12 months, Ionis Pharmaceuticals's stocks have ranged in value from as little as $34.43 up to $64.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 1.0865. This would suggest that Ionis Pharmaceuticals's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Stocks similar to Ionis Pharmaceuticals
Ionis Pharmaceuticals in the news
Ionis to hold second quarter 2021 financial results webcast
Ionis to hold second quarter 2021 financial results webcast
Hedge Funds Are Selling Ionis Pharmaceuticals, Inc. (IONS)
Frequently asked questions
More guides on Finder
How to buy Zevia PBC (ZVIA) stock in Canada
Everything we know about the Zevia PBC IPO, plus information on how to buy in.
How to buy Xponential Fitness (XPOF) stock in Canada
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
How to buy SOPHiA Genetics (SOPH) stock in Canada
Everything we know about the SOPHiA Genetics IPO, plus information on how to buy in.
How to buy Ryan Specialty Group Holdings (RYAN) stock in Canada
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
How to buy Ocean Biomedical (OCEA) stock in Canada when it goes public
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
How to buy Instructure Holdings (INST) stock in Canada
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
How to buy Gambling.com Group (GAMB) stock in Canada
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
How to buy Elicio Therapeutics (ELTX) stock in Canada when it goes public
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
How to buy Cytek Biosciences (CTKB) stock in Canada
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
How to buy Core & Main (CNM) stock in Canada
Everything we know about the Core & Main IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.